[Edaily Reporter NA EUN-KYUNG ] Drug delivery platform company Inventage Lab Inc.(389470)announced on the 6th that it will present research findings on mass production technology for messenger ribonucleic acid (mRNA)-lipid nanoparticles (LNP) based on its proprietary IVL-GeneFluidic® platform in a poster presentation at the “CRS 2026 Annual Meeting & Exposition,” an international conference in the field of drug delivery.

CRS (Controlled Release Society) is a leading international society in the fields of drug delivery and controlled release, serving as an academic conference where global pharmaceutical and biotech companies and research institutions share the latest drug delivery and manufacturing technologies. This year’s event will be held in Lisbon, Portugal, from July 6 to 9, and is expected to feature next-generation drug delivery technologies such as long-acting injectables (LAI), mRNA, nucleic acid therapeutics, and nanomedicines.

Recently, the scope of mRNA technology has expanded beyond COVID-19 vaccines to include cancer vaccines, treatments for rare diseases, and nucleic acid therapeutics. However, lipid nanoparticles (LNPs), which deliver mRNA into the body, have been identified as a major technical challenge for commercialization, as particle size and quality can vary during the scaling-up of manufacturing processes from the research stage to mass production.

Inventage Lab Inc. explained that through this research, it confirmed that by utilizing its microfluidics-based platform, “IVL-GenFluidic®,” and the “HandyGen™” series of manufacturing systems, it is possible to produce LNPs of consistent quality even as production scale is expanded from the R&D stage to commercial production.

In particular, the company confirmed that by applying “in-line dilution” technology—which simultaneously reduces solvent concentration during the LNP manufacturing process—it can maintain uniform particle characteristics regardless of production scale.

This research is also significant in that it demonstrates the company’s ability to implement an LNP manufacturing system using its own platform, rather than relying on equipment from overseas. The company expects this to facilitate the establishment of production systems tailored to the domestic environment, as well as technology transfer and the securing of supply chains.

The research results showed that the company was able to produce smaller and more uniform LNPs than with existing manufacturing methods using various types of RNA, including linear mRNA, self-amplifying mRNA, and circular mRNA. Furthermore, particle size and uniformity were stably maintained even when production was scaled up from small-scale research batches to commercial production levels. Production yield improved to a maximum of 89%, and biological efficacy was confirmed to be maintained, as the same immune response was observed in animal studies regardless of production scale.

Furthermore, consistent manufacturing performance was confirmed across all stages—from research and development to commercial production—using HandyGene™-LAB, HandyGene™-GMP, and HandyGene™-Commercial. The company expects that the ability to directly apply the manufacturing process established during the research phase to the production phase will help shorten process development time and reduce commercialization risks.

The IVL-GenFluidic® platform is a nucleic acid drug production platform that utilizes microfluidic technology to precisely manufacture LNPs. The company explains that because the manufacturing conditions established during the R&D phase can be scaled up to GMP and commercial production, the platform has potential applications not only for mRNA vaccines but also for the development of various RNA-based therapeutics.

An Inventage Lab Inc. official stated, “This study confirms that the IVL-GenFluidic® platform can maintain the same manufacturing competitiveness from R&D through commercial production,” adding, “We plan to expand domestic commercialization and technology transfer while continuing to pursue collaborations with global pharmaceutical companies.”

Meanwhile, this research was conducted with support from the Ministry of Trade, Industry and Energy’s “Technology Development Project for the Advancement of Vaccine Raw Material Production.”